January 2018 JAB-3000, Jacobio’s first new drug obtained FDA’s clinical trial license.
December 12 Jacobio submitted IND application for its first new drug JAB-3000 to CFDA and FDA.
November 2017 Jacomab Pharmaceuticals Co.,Ltd. was cofounded by Beijing Jacobio Pharmaceuticals Co. Ltd and Beijing Mabworks Biotech Co.Ltd.
September 2017 Jacobio Pharmaceuticals Co. Ltd. completed the “B round” of financing , invested firstly by Lily Asia Ventures of the U.S. and followed by Qiming Capital.
October 2016 Jacobio Pharmaceuticals Co. Ltd. completed the “A round” of financing .
February 2016 The second project company “Jacobio-Beta Pharmaceuticals Co., Ltd.” that was incubated by Jacobio Pharmaceuticals Co. Ltd was officially founded and registered.
January, 2016 The first project company “Jacobio-Alpha Pharmaceuticals Co. Ltd.” that was incubated by Jacobio Pharmaceuticals Co. Ltd was officially founded and registered.
November, 2015 Beijing Jacobio Pharmaceuticals Co. Ltd. moved its headquarter to the 5th building of Beijing Yizhuang Biomedical Park which owned a 4000m² R&D space.
September, 2015 “Beijing Yitang Jacobio Venture Investment Center (LP)” Foundation was founded by Beijing E-TOWN Capital, Ltd and Jacobio Pharmaceuticals Co. Ltd. with first investment of 200 million.
April, 2015 Jacobio Pharmaceuticals Co. Ltd. was founded in a 600m² lab located in the 10th floor of the Incubator Building in Beijing Yizhuang Biomedical Park.